Schonfeld Strategic Advisors’s AbbVie ABBV Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.2M	Buy	104,287 +51,227	+97%	+$11M	0.09%	187
2026 Q1	$11.5M	Buy	53,060 +32,932	+164%	+$7.31M	0.08%	266
2025 Q4	$4.6M	Sell	20,128 -12,353	-38%	-$2.81M	0.02%	572
2025 Q3	$7.52M	Buy	32,481 +21,931	+208%	+$4.47M	0.04%	438
2025 Q2	$1.96M	Sell	10,550 -2,607	-20%	-$485K	0.01%	1002
2025 Q1	$2.76M	Sell	13,157 -120	-0.9%	-$23.3K	0.02%	799
2024 Q4	$2.36M	Sell	13,277 -471	-3%	-$86.6K	0.01%	767
2024 Q3	$2.71M	Buy	13,748 +5,063	+58%	+$945K	0.02%	762
2024 Q2	$1.49M	Buy	8,685 +5,545	+177%	+$919K	0.01%	1034
2024 Q1	$572K	Buy	+3,140	New	+$541K	﹤0.01%	1432
2023 Q4	–	Sell	-4,890	Closed	-$729K	–	1826
2023 Q3	$729K	Buy	4,890 +3,235	+195%	+$475K	0.01%	1111
2023 Q2	$223K	Sell	1,655 -58,209	-97%	-$8.54M	﹤0.01%	1512
2023 Q1	$9.54M	Buy	59,864 +964	+2%	+$147K	0.09%	294
2022 Q4	$9.52M	Sell	58,900 -13,260	-18%	-$2.03M	0.08%	309
2022 Q3	$9.68M	Buy	72,160 +70,396	+3,991%	+$10.1M	0.08%	317
2022 Q2	$271K	Sell	1,764 -3,236	-65%	-$494K	﹤0.01%	1728
2022 Q1	$810K	Sell	5,000 -22,465	-82%	-$3.26M	0.01%	1096
2021 Q4	$3.72M	Sell	27,465 -29,614	-52%	-$3.5M	0.03%	536
2021 Q3	$6.16M	Sell	57,079 -52,126	-48%	-$5.96M	0.06%	380
2021 Q2	$12.3M	Buy	109,205 +50,885	+87%	+$5.73M	0.13%	239
2021 Q1	$6.31M	Buy	58,320 +16,192	+38%	+$1.73M	0.08%	351
2020 Q4	$4.51M	Sell	42,128 -20,944	-33%	-$2.01M	0.06%	412
2020 Q3	$5.53M	Buy	63,072 +37,867	+150%	+$3.57M	0.11%	265
2020 Q2	$2.47M	Buy	25,205 +2,744	+12%	+$242K	0.06%	351
2020 Q1	$1.71M	Buy	+22,461	New	+$1.91M	0.11%	230
2019 Q4	–	Sell	-77,300	Closed	-$5.85M	–	1265
2019 Q3	$5.85M	Sell	77,300 -511	-0.7%	-$35K	0.17%	153
2019 Q2	$5.66M	Buy	77,811 +63,735	+453%	+$5.01M	0.2%	123
2019 Q1	$1.13M	Buy	+14,076	New	+$1.15M	0.04%	473
2018 Q3	–	Sell	-16,980	Closed	-$1.57M	–	781
2018 Q2	$1.57M	Sell	16,980 -41,994	-71%	-$4.1M	0.09%	313
2018 Q1	$5.58M	Buy	58,974 +8,835	+18%	+$971K	0.42%	58
2017 Q4	$4.85M	Buy	50,139 +41,139	+457%	+$3.88M	0.4%	71
2017 Q3	$800K	Buy	+9,000	New	+$685K	0.07%	301
2017 Q2	–	Sell	-11,098	Closed	-$723K	–	594
2017 Q1	$723K	Sell	11,098 -130,306	-92%	-$8.19M	0.07%	306
2016 Q4	$8.86M	Buy	141,404 +129,104	+1,050%	+$7.88M	1.15%	5
2016 Q3	$776K	Buy	+12,300	New	+$796K	0.13%	212

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Schonfeld Strategic Advisors's ABBV Position: Q2 2026 in Review

Schonfeld Strategic Advisors increased its AbbVie (ABBV) stake by 97% in Q2 2026, buying an estimated $11M and bringing the position to 104,287 shares worth $26.2M. The position accounts for 0.09% of the portfolio, ranked #187.

Schonfeld Strategic Advisors first reported a position in ABBV in Q3 2016 and has held it in 35 quarters since. 4,192 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Schonfeld Strategic Advisors held 104,287 shares of AbbVie worth $26.2M as of Q2 2026.
Schonfeld Strategic Advisors bought 51,227 AbbVie shares in Q2 2026, an estimated $11M.
AbbVie made up 0.09% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #187 holding.
Schonfeld Strategic Advisors first reported a position in AbbVie in Q3 2016 and has held it in 35 quarters since.
4,192 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.